Aclarion's Nociscan launches at first Indiana provider site

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, making it the first site in Indiana to offer the technology, according to a company press release.

Nociscan uses Magnetic Resonance Spectroscopy to extract and quantify chemical biomarkers associated with disc pain, allowing physicians to distinguish between painful and nonpainful discs in the lumbar spine. The company states the platform demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.

Dr. Eric A. Potts, a neurosurgeon and spine specialist at Goodman Campbell Brain & Spine and past chair of the American Association of Neurological Surgeons/Congress of Neurological Surgeons Joint Section on Disorders of the Spine and Peripheral Nerves, commented on the addition: "Every patient we see with chronic low back pain deserves a clear answer about where their pain is coming from before we talk about treatment. For years, MRI alone hasn't been able to give us that answer — it shows us the anatomy, but not which disc is actually the source of pain."

Brent Ness, CEO of Aclarion, said the addition of each new site "reflects the growing momentum behind Nociscan adoption" as the company works to expand access to the technology.

The partnership extends Aclarion's provider network into Indiana. Aclarion is based in Broomfield, Colorado, and describes itself as a commercial-stage healthcare technology company. Approximately 266 million people worldwide are reported to suffer from degenerative spine disease and low back pain, according to the press release.

You May Also Be Interested In

• JPMorgan Reiterates Overweight Rating on Legrand SA (LR:FP) (LGRDY) and Places on Positive Catalyst Watch
• Jefferies Upgrades Energean Oil & Gas (ENOG:LN) (EERGF) to Hold
• Motilal Oswal Securities Starts V2 Retail Ltd (VREL:IN) at Buy